276
Participants
Start Date
January 17, 2013
Primary Completion Date
April 30, 2017
Study Completion Date
November 27, 2019
EnligHTN
Renal artery ablation with EnligHTN system used for all groups
Royal Melbourne Hospital - City Campus, Parkville
The Prince Charles Hospital, Chermside
Uni-Klinik Leipzig, Intervent. Angiologie, Leipzig
Royal Adelaide Hospital, Adelaide
Royal Perth Hospital, Perth
St. Olavs University Hospital, Trondheim
Dunedin Public Hospital, Dunedin
Jüdisches Krankenhaus Berlin, Berlin
Hospital Universitario Donostia, San Sebastián
Centro Cardiologico Monzino, Milan
CHU de Besancon - Jean Minjoz, Besançon
Herz-und Diabetes Zentrum NRW, Bad Oeynhausen
Policlinico S.Orsola Malpighi, Bologna
Universitatsklinikum Essen (AoR), Essen
Fondazione Toscana Gabriele Monasterio CNR, Massa
Krankenhaus der Barmherzigen Bruder, Trier
Klinikum der Johannes-Gutenberg-Universitat, Mainz
Kerckhoff-Klinik gGmbH, Bad Nauheim
Universitatsklinikum des Saarlandes, Homburg
Hopital Civil - Universitaires de Strasbourg, Strasbourg
Hopital de la Croix Rousse, Lyon
Universitats-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen
Klinikum Ingolstadt GmbH, Ingolstadt
Klinikum Coburg GmbH, Coburg
Institute Cardio. Paris-Sud-Institut Jacques Cartier, Paris
St-Etienne CHU, Saint-Etienne
University of Athens, Ippocration Hospital, Athens
Haukeland Universitetssykehus, Bergen
Haga Ziekenhuis Locatie Leyenburg, The Hague
UMC Utrecht, Utrecht
Sahlgrenska University Hospital Gothenburg, Gothenburg
NIHR Barts Cardiovascular Biomedical Research Unit, London
Northern General Hospital, Sheffield
Lead Sponsor
Abbott Medical Devices
INDUSTRY